Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - Ardea Biosciences, Inc./DE | a58282exv99w2.htm |
| EX-99.1 - EX-99.1 - Ardea Biosciences, Inc./DE | a58282exv99w1.htm |
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 6, 2011
Ardea Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 1-33734 | 94-3200380 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
| 4939 Directors Place | 92121 | |
| San Diego, California | (Zip Code) | |
| (Address of principal executive offices) |
Registrant’s telephone number, including area code: (858) 652-6500
Not applicable.
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
| Item 7.01. Regulation FD Disclosure | ||||||||
| Item 9.01. Financial Statements and Exhibits. | ||||||||
| SIGNATURE | ||||||||
| EXHIBIT LIST | ||||||||
| EX-99.1 | ||||||||
| EX-99.2 | ||||||||
Table of Contents
| Item 7.01. | Regulation FD Disclosure |
The
Company has recently received and publicly announced certain clinical
data related to certain of its
products. A copy of the press release announcing the data and a related live conference call and
webcast to discuss the data is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by
reference in its entirety.
A copy of presentation materials describing the Company’s business to be used in the conference
call and webcast and from time to time thereafter is filed as Exhibit 99.2 hereto. These materials
reflect updates to information previously furnished by the Company
regarding certain of the Company’s research
and development programs. The Company does not intend to file any update of these presentation
materials in the future. The fact that these updated presentation materials are being furnished
should not be deemed an admission as to the materiality of any information contained in the
materials.
The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, except as shall be
expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:
| Exhibit | ||
| Number | Document Description | |
99.1
|
Press release dated January 6, 2011. | |
99.2
|
Ardea Biosciences, Inc. presentation materials dated as of January 6, 2011, and to be used from time to time thereafter. |
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| ARDEA BIOSCIENCES, INC. |
||||
| Date: January 6, 2011 | /s/ CHRISTIAN WAAGE | |||
| Christian Waage | ||||
| General Counsel | ||||
Table of Contents